Key result
SGLT2 inhibitors improve cardiovascular outcomes in HFpEF and HFmrEF regardless of diabetes.
Why the study?
The study was conducted to provide a pooled effect of SGLT2 inhibitors on cardiovascular outcomes in patients with HFpEF or/and HFmrEF regardless of baseline diabetes.
Do SGLT2 inhibitors reduce cardiovascular death and/or urgent visits/hospitalization for heart failure in patients with heart failure with preserved or mildly reduced ejection fraction regardless of baseline diabetes?
Meta-Analysis
Do SGLT2 inhibitors reduce cardiovascular death and/or urgent visits/hospitalization for heart failure in patients with heart failure with preserved or mildly reduced ejection fraction regardless of baseline diabetes?
This meta-analysis supports SGLT2 inhibitors as a foundational therapy for patients with heart failure with preserved or mildly reduced ejection fraction, regardless of diabetes status.
Supports SGLT2 inhibitor initiation as standard in HFpEF/HFmrEF regardless of diabetes; confirms benefit across pooled RCTs.
AIM: To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF: ≥50%) or/and mildly reduced EF (HFmrEF: 41-49%) regardless of baseline diabetes. METHODS: We systemically searched PubMed/MEDLINE, Embase, Web of Science databases and clinical trial registries using appropriate keywords till August 28, 2022, to identify randomized controlled trials (RCTs) or post-hoc analysis of RCTs, reporting cardiovascular death (CVD) and/or urgent visits/hospitalization for heart failure(HHF) in patients with HFmrEF/HFpEF receiving SGLTi vs. placebo. Hazard ratios (HR) with 95% confidence intervals (CI) for outcomes were pooled together using generic inverse variance method with fixed-effects model. CONCLUSIONS: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2023) conducted a meta-analysis in Heart failure with mildly reduced and preserved ejection fraction. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. Placebo was evaluated on Cardiovascular death and/or urgent visits/hospitalization for heart failure. SGLT2 inhibitors serve as a foundational therapy for cardiovascular outcomes in patients with heart failure with preserved and mildly reduced ejection fraction regardless of diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on HFrEF treatmentMore from Indian Heart Journal